San Diego-based Cypher Genomics has been offering human genome interpretation software. The company's 14 employees will join Human Longevity.
The partners will use Cypher's software to diagnose rare diseases in the Clinic's unique patient population, which includes Amish and Mennonite patients.
With funding from CurePSP, the collaborators will investigate the genetic causes of the disease, which affects a patients' speech, mobility, balance, and other abilities.
The updated Mantis provides researchers a tool for the automated interpretation of cancer-related somatic variants, including variants of unknown significance.
The BeHEARD competition will award more than $600,000 worth of technology products and services for rare disease research projects.
Sequenom will use Cypher's genome interpretation technology, Mantis, to analyze clinically relevant fetal sub-chromosomal variants detected in maternal blood.
Cypher Genomics said this week that it is offering trial access to Mantis, its genome interpretation technology through a newly launched program called Mantis 5-for-5.
Rubicon Genomics has hired Karl Hecker as vice president of product development. Previously, he was a principal scientist at HTG Molecular Diagnostics. He has also held positions at Quidel, PerkinElmer, Invitrogen, and Transgenomic.
Maverix Biomics has added Jim Bristow to its scientific advisory board.
Cypher Genomics has appointed Adam Simpson as president and chief operating officer.
The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.
The Associated Press reports that gene-edited food may soon be for sale.
The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.
In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.